human pluripotent stem cells derived allogenic hepatocytes (GoLiver Therapeutics)

N/A

Report date: 2025/01/26 18:00:30

Base Information

Drug Namehuman pluripotent stem cells derived allogenic hepatocytes (GoLiver Therapeutics)

Drug Alias Namehuman pluripotent stem cells derived allogenic hepatocytes (INSERM)human pluripotent stem cells derived allogenic hepatocytes (Universite de Nantes)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hepatogenic potential stem cell therapy

Mechanisms of ActionHepatocyte stimulants

TargetsUpdating

Therapy Area/IndicationsLiver Failure, AcuteMetabolic Dysfunction-Associated Steatotic Liver DiseaseLiver Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited KingdomFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGoliver Therapeutics SAS

China Registration ClassN/A

Develop Information

Active CompaniesGoliver Therapeutics SAS

Inactive CompaniesN/A

Active IndicationsLiver Failure, AcuteMetabolic Dysfunction-Associated Steatotic Liver DiseaseLiver Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A